drugset / Trial / NCT00465738

IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity

NCT00465738 ↗

Phase 3 Completed 216 enrolled Merz Pharmaceuticals GmbH
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of arm tightness (upper limb spasticity) using two different dilutions of incobotulinumtoxinA (Xeomin).

Timeline

Start
2007-02
Primary completion
2008-01
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 20 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 50 iu Intramuscular

Indications

No indication recorded.